To avoid artificial transient protein interactions triggered by high cellular expression levels of HMGA2-biotin ligase fusion protein in our BPL studies, we selected HEK293 stable transfectants that expressed HMGA2-BioID2 and HMGA2-miniTurbo at low to medium levels, comparable to the HMGA2 protein levels detected in cancer cells. Here, HMGA2 is linked to cancer.